Kidney disease and cancer are frequent comorbidities that require specialized knowledge and expertise from both the nephrologist and the oncologist. Written by three pioneers in this growing subspecialty, Onco-Nephrology provides authoritative, definitive coverage of the mechanism and management of these two life-threatening diseases. This unique, single-volume resource covers current protocols and recommends management therapies to arrest kidney failure and allow oncologic treatments to continue and succeed. Addresses acute and chronic kidney diseases that develop from a variety of cancers. This includes direct kidney injury from the malignancy, paraneoplastic effects of the cancer, and various cancer agents used to treat the malignancy. Discusses key issues regarding kidney disease in patients with cancer, including conventional chemotherapeutic regimens and new novel therapies (targeted agents and immunotherapies) or the malignancies themselves that may promote kidney injury; patients with chronic kidney disease who acquire cancer unrelated to renal failure; and kidney transplantation, which has been shown to carry an increased risk of cancer. Contains dedicated chapters for each class of the conventional chemotherapeutic agents, targeted cancer agents, and cancer immunotherapies including the basic science, pathogenic mechanisms of injury, clinical manifestations, and treatment. Includes special chapters devoted to the individual classes of chemotherapies that relate to kidney disease for quick reference. Discusses increasingly complex problems due to more numerous and specialized anti-cancer drugs, as well as increased survival rates for both cancer and renal failure requiring long-term patient care. Covers anti-VEGF (antivascular endothelial growth factor) agents and cancer immunotherapies – treatments that are being recognized for adverse kidney effects. Utilizes a clear, logical format based on the ASN Core Curriculum for Onco-Nephrology, making this reference an excellent tool for board review, as well as a practical resource in daily practice.
This unique, single-volume resource covers current protocols and recommends management therapies to arrest kidney failure and allow oncologic treatments to continue and succeed.
Filling a significant knowledge gap in this burgeoning field, Onconephrology features the latest evidence and clinical approaches for the beginner or experienced practitioner.
Enjoy faster, easier review and master the top issues in nephrology with mnemonics, lists, quick-reference tables, and an informal tone that sets this review book apart from the rest.
Haas, M. (2009). ABO Incompatible renal transplantation: A paradigm ready for broad implementation. Transplantation, 87, 1246–1255. Reeves, H. M., & Winters, J. L. (2014). The mechanisms. 390 TREATMENT OPTIONS Bibliography.
Cancer and the Kidney covers the challenging overlap area of nephrology and oncology, both in terms of kidney problems in cancer patients, and cancer that affects kidney patients, including assessment of kidney function, to paraneoplastic ...
An eBook version is included with purchase. The eBook allows you to access all of the text, figures and references, with the ability to search, customize your content, make notes and highlights, and have content read aloud.
... OF THE KIDNEY TRANSPLANT RECIPIENT 424 Beje Thomas and Matthew R. Weir XII HYPERTENSION CHAPTER 62 PRIMARY HYPERTENSION 431 Hillel Sternlicht and George L. Bakris CHAPTER 63 KIDNEY PARENCHYMAL HYPERTENSION 438 Martin J. Andersen, ...
Chauvet V, Tian X, Husson H et al: Mechanical stimuli induce cleavage and nuclear translocation of the polycystin-1 C terminus, J Clin Invest 114:1433-43, 2004. Low SH, Vasanth S, Larson CH et al: Polycystin-1, STAT6, and P100 function ...
Bankston PW, Milici AJ. A survey of the binding of polycationic ferritin in several fenestrated capillary beds: indication of heterogeneity in the luminal glycocalyx offenestral diaphragms. Microvasc Res. 1983;26:36-48.
Nurses care for patients with acute, chronic, and end-stage kidney disease in all patient care settings. Early recognition of risk and disease can improve health outcomes and delay progression of disease.